What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 12.7% in the afternoon session after the company announced its TETON-...
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ...
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Shares of biotechnology company United Therapeutics (NASDAQ:UTHR)
fell 7.2% in the afternoon session after the company reported fourth-quarter financial results that missed revenue expectations, overshadowing an earnings beat.
United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company cemented its status as a high-performance healthcare powerhouse by reporting a significant Q4 2025 earnings beat and officially surpassing the $3 billion annual revenue milestone for [...]
As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary arterial hypertension (PAH), the company has recently captured Wall Street’s attention with a series of high-stakes maneuvers. Following a stellar Q4 2025 earnings report released [...]
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 7.4% year on year to $790.2 million. Its GAAP profit of $7.70 per share was 14% above analysts’ consensus estimates.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with United Therapeutics (NASDAQ:UTHR).
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).
